Similarly, in two other clinical trials, patients with NAFLD taking amorphous curcumin preparations (500 mg/d) or phospholipid curcumin capsules (500 mg bid) showed significant reductions in AST and ALT levels, significant reductions in liver fat content and improvements in NAFLD severity [5,58]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.